MedTrace Logo

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

NCT06992440 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-12-17

No results posted yet for this study

Summary

Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.

Conditions

Interventions

DRUG

Empagliflozin 10 MG

10 mg tablet once daily

DRUG

Placebo

matching tablet once daily

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Gustavo A Heresi, MD, MS

    lead OTHER

Principal Investigators

  • Gustavo Heresi, MD · The Cleveland Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-26
Primary Completion
2030-07-31
Completion
2030-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06992440 on ClinicalTrials.gov